Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Pain, Cancer

In brief

To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.

Key facts

Study ID

NCT00492388

Run by

Hospira, now a wholly owned subsidiary of Pfizer

People needed

2

Starts

2007-06-01

Expected to finish

2011-08-01

Last updated by the study team

2012-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• at least 18 years of age
• Patients requiring around-the-clock opioids for pain due to cancer and with a history of experiencing episodes of breakthrough pain

You may not qualify if…

• under 18 years
• non-cancer pain
• allergy to ketamine

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.